Synergy's IBS drug delivers positive top-line results in mid-stage trial

Synergy Pharmaceuticals' (SGYP) plecanatide shows a statistically significant improvement in complete spontaneous bowel movement (CSBM) frequency in patients with irritable bowel syndrome with constipation (IBS-C) in a Phase 2b clinical trial.

Patients also experienced a statistically significant improvement in change from baseline versus placebo in worst abdominal pain and met the FDA overall responder endpoint for IBS-C over the 12-week treatment period.

The company plans to start a Phase 3 trial in the second half.

Shares are up 5% premarket on robust volume.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs